TY - JOUR AU - Liam, Chong-Kin PY - 2019 TI - Central nervous system activity of first-line osimertinib in epidermal growth factor receptor-mutant advanced non-small cell lung cancer JF - Annals of Translational Medicine; Vol 7, No 3 (February 01, 2019): Annals of Translational Medicine Y2 - 2019 KW - N2 - Although the majority of patients with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)- sensitizing mutations experience good initial response to first‑generation (erlotinib, gefitinib) and second-generation (afatinib, dacomitinib) EGFR-TKIs, they invariably suffer disease progression either due to a pharmacodynamic resistance to the EGFR-TKI or a pharmacokinetic failure resulting in central nervous system (CNS) progression (1-3). UR - https://atm.amegroups.org/article/view/23427